31 related articles for article (PubMed ID: 9447285)
1. Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist.
Miyazawa Y; Kato H; Arai S; Furuya Y; Sekine Y; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Basic Clin Androl; 2015; 25():7. PubMed ID: 26146562
[TBL] [Abstract][Full Text] [Related]
2. Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration.
Zaitsu M; Yamanoi M; Mikami K; Takeshima Y; Okamoto N; Imao S; Tonooka A; Takeuchi T
Adv Urol; 2012; 2012():979154. PubMed ID: 21754927
[TBL] [Abstract][Full Text] [Related]
3. Diethylstilbestrol in the Treatment of Castration-resistant Prostate Cancer: A Lower-middle-income Country Experience.
Ali A; Khalil MAI; Khan N; Abu Bakar M; Amjad A; Ahmed I; Mir K
Cureus; 2019 Apr; 11(4):e4470. PubMed ID: 31249748
[TBL] [Abstract][Full Text] [Related]
4. Transdermal estradiol in castrate and chemotherapy resistant prostate cancer.
Stein M; Goodin S; Doyle-Lindrud S; Silberberg J; Kane M; Metzger D; Eddy S; Shih W; DiPaola RS
Med Sci Monit; 2012 Apr; 18(4):CR260-4. PubMed ID: 22460098
[TBL] [Abstract][Full Text] [Related]
5. Experimental use of GnRH antagonists as second-line hormonal therapy.
Beer TM
Rev Urol; 2004; 6 Suppl 7(Suppl 7):S33-8. PubMed ID: 16985935
[TBL] [Abstract][Full Text] [Related]
6. Possibility of recovery of estrogen sensitivity following high-dose glucocorticoid therapy in a patient with hormone-refractory prostate cancer.
Yamamoto S; Yonese J; Kawakami S; Tsukamoto T; Ohkubo Y; Tatokoro M; Fukui I
Int J Clin Oncol; 2006 Aug; 11(4):326-8. PubMed ID: 16937308
[TBL] [Abstract][Full Text] [Related]
7. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer.
Perez-Marrero R; Tyler RC
Expert Opin Pharmacother; 2004 Feb; 5(2):447-57. PubMed ID: 14996640
[TBL] [Abstract][Full Text] [Related]
8. Hormonal therapy of prostate cancer.
Debruyne F
Semin Urol Oncol; 2002 Aug; 20(3 Suppl 1):4-9. PubMed ID: 12198632
[TBL] [Abstract][Full Text] [Related]
9. Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer.
Kitahara S; Umeda H; Yano M; Koga F; Sumi S; Moriguchi H; Hosoya Y; Honda M; Yoshida K
Endocr J; 1999 Oct; 46(5):659-64. PubMed ID: 10670751
[TBL] [Abstract][Full Text] [Related]
10. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
11. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of disease flare with diethylstilbestrol diphosphate and chlormadinone acetate administration for two weeks prior to slow-releasing leuprolide acetate in prostatic cancer patients.
Ohuchi H; Noguchi K; Kinoshita Y; Hosaka M; Kawasaki C; Miura T; Kondo I; Harada M
Hinyokika Kiyo; 2000 Aug; 46(8):531-6. PubMed ID: 11019371
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
[TBL] [Abstract][Full Text] [Related]
14. Stronger suppression of serum testosterone and FSH levels by a synthetic estrogen than by castration or an LH-RH agonist.
Kitahara S; Yoshida K; Ishizaka K; Kageyama Y; Kawakami S; Tsujii T; Oshima H
Endocr J; 1997 Aug; 44(4):527-32. PubMed ID: 9447285
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
